Blood clues could unlock new ewing sarcoma treatments

NCT ID NCT07685405

Recruiting now Knowledge-focused Sponsor: Istituto Ortopedico Rizzoli Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study examines blood samples from people with Ewing sarcoma to find circulating biomarkers—substances that might signal the presence or behavior of the cancer. Researchers will compare samples from patients and healthy volunteers to identify markers that could help validate new treatments. The goal is to lay groundwork for more targeted therapies in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could point toward new ways to detect or treat Ewing sarcoma by using blood-based markers.
What could go wrong: This is a very small, early feasibility study with only 16 participants, so findings may not apply broadly or lead directly to treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARCOMA, EWING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ewing sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARCOMA, EWING

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Istituto ortopedico Rizzoli Laboratorio di Ricerc Oncologica e Genomica funzioanle
RECRUITING

Bologna, BO, 40136, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.